2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMORecruiting
The primary objective is to assess the effect of ICU-VR, offered early (within two weeks after ICU discharge) or late (three months after ICU discharge during an ICU follow-up clinic), on the severity of PTSD-related symptoms six months after ICU…